Is there any way to gauge how the FDA will respond to the generic Lovenox applicants? In particular who is notified first? Would they be inclined to announce a denial first before an approval or vice versa.
There is no clear-cut order for these actions.
If TEVA were to find out they got denied before MNTA was notified of an approval/denial. would MNTA share price go up or down?
Rejection of Teva’s ANDA combined with no FDA action on MNTA/NVS’ ANDA would make MNTA’s share price go up, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”